SuperworthAIM ImmunoTech price to sales ratio AIM
Market value divided by revenue over the last twelve months, since 2012.
- Today, Oct 23, 2026
- 50.1×
- 10-year median
- 58.5×
- Against its 10-year history
- 42nd
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 10.0× to 198×
- Peer median
- 1.4×
AIM ImmunoTech's price to sales ratio is 50.1× as of Oct 23, 2026.
That is below its ten-year median of 58.5×, close to the middle of its last ten years.
Over that time it ranged from 10.0× in Aug 2019 to 198× in Sep 2022.
The median for 10 healthcare stocks of a similar size is 1.4×.
Price to sales ratio over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 50.1× | 17.7× | 82.8× |
| 2025 | 31.8× | 12.0× | 72.6× |
| 2024 | 66.3× | 60.0× | 130× |
| 2023 | 105× | 102× | 196× |
| 2022 | 105× | 105× | 198× |
| 2021 | n/m a value too high to mean anything | ||
| 2020 | n/m a value too high to mean anything | ||
| 2019 | 10.0× | 10.0× | 58.9× |
| 2018 | 48.7× | 24.4× | 58.9× |
| 2017 | 26.0× | 23.7× | 194× |
| 2016 | 152× | 112× | 199× |
| 2015 | 128× | 112× | 194× |
| 2014 | n/m a value too high to mean anything | ||
| 2013 | 189× | 140× | 198× |
| 2012 | 194× | 167× | 194× |
Against its peers
Companies in Healthcare nearest AIM ImmunoTech's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| AIMAIM ImmunoTech | 50.1× |
| OXBROXBRIDGE RE HOLDINGS | 2.8× |
| EDUCEducational Development | 0.4× |
| GTIMGood Times Restaurants | 0.1× |
| MDRRMedalist Diversified | 1.6× |
| BCGBinah Capital | 0.1× |
| VIPVulcan Infrastructure & Power | 0.4× |
| MXCMexco Energy | 3.0× |
| CKXCKX Lands | 31.0× |
| MSGMMotorsport Games | 1.5× |
| ATCHAtlasClear | 1.2× |
| Peer median | 1.4× |
Where AIM ImmunoTech ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on AIM ImmunoTech
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.